Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients (60% and 58%) experienced clinically meaningful itch.
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing
Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old 68% of children
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are.